{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T10:45:35Z","timestamp":1792233935669,"version":"4.4.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"S1","license":[{"start":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T00:00:00Z","timestamp":1747353600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T00:00:00Z","timestamp":1747353600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA046934"],"award-info":[{"award-number":["P30CA046934"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Surviv"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s11764-025-01797-2","type":"journal-article","created":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T20:34:35Z","timestamp":1747341275000},"page":"329-336","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Financial burden of high-cost immunotherapy among cancer survivors in Medicare"],"prefix":"10.1007","volume":"20","author":[{"given":"Kelsey M.","family":"Owsley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cathy J.","family":"Bradley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,16]]},"reference":[{"issue":"5","key":"1797_CR1","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1038\/nrc.2017.17","volume":"17","author":"P Gotwals","year":"2017","unstructured":"Gotwals P, et al. Prospects for combining targeted and conventional cancer therapy with immunotherapy. Nat Rev Cancer. 2017;17(5):286\u2013301.","journal-title":"Nat Rev Cancer"},{"key":"1797_CR2","doi-asserted-by":"crossref","unstructured":"Warwar SC, Janczewski LM, Rodriguez GM, Wayne JD, Bentrem DJ. Trends in immunotherapy (IO) use and survival among patients with high\u2010incidence stage IV cancers across the United States. J Surg Oncol\u00a02025.","DOI":"10.1002\/jso.28084"},{"issue":"22","key":"1797_CR3","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","volume":"378","author":"L Gandhi","year":"2018","unstructured":"Gandhi L, et al. Pembrolizumab plus chemotherapy in metastatic non\u2013small-cell lung cancer. N Engl J Med. 2018;378(22):2078\u201392.","journal-title":"N Engl J Med"},{"issue":"10183","key":"1797_CR4","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1016\/S0140-6736(18)32409-7","volume":"393","author":"TS Mok","year":"2019","unstructured":"Mok TS, et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet. 2019;393(10183):1819\u201330.","journal-title":"Lancet"},{"issue":"2","key":"1797_CR5","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1001\/jamaoncol.2018.4514","volume":"5","author":"PA Ascierto","year":"2019","unstructured":"Ascierto PA, et al. Survival outcomes in patients with previously untreated BRAF wild-type advanced melanoma treated with nivolumab therapy: three-year follow-up of a randomized phase 3 trial. JAMA Oncol. 2019;5(2):187\u201394.","journal-title":"JAMA Oncol"},{"issue":"7","key":"1797_CR6","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1056\/NEJMoa1916623","volume":"383","author":"N Howlader","year":"2020","unstructured":"Howlader N, et al. The effect of advances in lung-cancer treatment on population mortality. N Engl J Med. 2020;383(7):640\u20139.","journal-title":"N Engl J Med"},{"issue":"1","key":"1797_CR7","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1377\/hlthaff.2015.0830","volume":"35","author":"MP Banegas","year":"2016","unstructured":"Banegas MP, et al. For working-age cancer survivors, medical debt and bankruptcy create financial hardships. Health Aff. 2016;35(1):54\u201361.","journal-title":"Health Aff"},{"key":"1797_CR8","doi-asserted-by":"crossref","unstructured":"Altice CK, Banegas MP, Tucker-Seeley RD, Yabroff KR. Financial hardships experienced by cancer survivors: a systematic review. J Nat Can Inst\u00a02017;109(2)djw205.","DOI":"10.1093\/jnci\/djw205"},{"key":"1797_CR9","doi-asserted-by":"crossref","unstructured":"Doroudi M, Coughlan D, Banegas MP, Han X, Robin Yabroff K. Is cancer history associated with assets, debt, and net worth in the United States?\u00a0JNCI Cancer Spectrum 2018;2(2)pky004.","DOI":"10.1093\/jncics\/pky004"},{"key":"1797_CR10","doi-asserted-by":"crossref","unstructured":"Carrera PM, Kantarjian HM, Blinder VS. The financial burden and distress of patients with cancer: understanding and stepping\u2010up action on the financial toxicity of cancer treatment. CA: a Can J Clin 2018;68(2)153\u2013165.","DOI":"10.3322\/caac.21443"},{"issue":"5","key":"1797_CR11","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1016\/j.juro.2017.10.049","volume":"199","author":"MM Casilla-Lennon","year":"2018","unstructured":"Casilla-Lennon MM, et al. Financial toxicity among patients with bladder cancer: reasons for delay in care and effect on quality of life. J Urol. 2018;199(5):1166\u201372.","journal-title":"J Urol"},{"key":"1797_CR12","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/s00520-020-05468-z","volume":"29","author":"ES Ver Hoeve","year":"2011","unstructured":"Ver Hoeve ES, Ali-Akbarian L, Price SN, Lothfi NM, Hamann HA. Patient-reported financial toxicity, quality of life, and health behaviors in insured US cancer survivors. Support Care Cancer. 2011;29:349\u201358.","journal-title":"Support Care Cancer"},{"key":"1797_CR13","doi-asserted-by":"crossref","unstructured":"Yabroff\u00a0KR\u00a0et al. Association of medical financial hardship and mortality among cancer survivors in the United States. JNCI: J Nat Cancer Inst\u00a02022;114(6)863\u2013870.","DOI":"10.1093\/jnci\/djac044"},{"issue":"2","key":"1797_CR14","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1158\/1055-9965.EPI-19-0460","volume":"29","author":"X Han","year":"2020","unstructured":"Han X, Zhao J, Zheng Z, de Moor JS, Virgo KS, Yabroff KR. Medical financial hardship intensity and financial sacrifice associated with cancer in the United States. Cancer Epidemiol Biomark Prev. 2020;29(2):308\u201317.","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"1797_CR15","doi-asserted-by":"crossref","unstructured":"Shih YCT, Owsley KM, Nicholas LH, Yabroff KR, Bradley CJ. Cancer\u2019s lasting financial burden: evidence from a longitudinal assessment. JNCI: J Nat Cancer Inst\u00a02022;114(7):1020\u20131028","DOI":"10.1093\/jnci\/djac064"},{"key":"1797_CR16","unstructured":"IQVIA. \u201cGlobal oncology trends in 2023.\u201d https:\/\/www.iqvia.com\/insights\/the-iqvia-institute\/reports-and-publications\/reports\/global-oncology-trends-2023. Accessed 8\/1\/2024."},{"issue":"4","key":"1797_CR17","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/s40261-023-01254-x","volume":"43","author":"YE Shin","year":"2023","unstructured":"Shin YE, Kumar A, Guo JJ. Spending, utilization, and price trends for immune checkpoint inhibitors in US medicaid programs: an empirical analysis from 2011 to 2021. Clin Drug Investig. 2023;43(4):289\u201398.","journal-title":"Clin Drug Investig"},{"key":"1797_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40425-018-0442-7","volume":"6","author":"V Verma","year":"2018","unstructured":"Verma V, et al. A systematic review of the cost and cost-effectiveness studies of immune checkpoint inhibitors. J Immunother Cancer. 2018;6:1\u201315.","journal-title":"J Immunother Cancer"},{"key":"1797_CR19","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_397912","volume":"43","author":"ERS Cliff","year":"2023","unstructured":"Cliff ERS, et al. High cost of chimeric antigen receptor T-cells: challenges and solutions. Am Soc Clin Oncol Educ Book. 2023;43: e397912.","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"3","key":"1797_CR20","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001901","volume":"9","author":"TU Marron","year":"2021","unstructured":"Marron TU, et al. Considerations for treatment duration in responders to immune checkpoint inhibitors. J Immunother Cancer. 2021;9(3): e001901.","journal-title":"J Immunother Cancer"},{"issue":"11","key":"1797_CR21","doi-asserted-by":"publisher","DOI":"10.1002\/cnr2.1720","volume":"5","author":"RD Bachu","year":"2022","unstructured":"Bachu RD, et al. Oncology biosimilars: new developments and future directions. Cancer Reports. 2022;5(11): e1720.","journal-title":"Cancer Reports"},{"key":"1797_CR22","unstructured":"Ferro C, Fitch K, Pittinger S. The cost burden of blood cancer care in Medicare: a longitudinal analysis of Medicare advantage and fee for service patients diagnosed with blood cancer. Milliman Research Report. https:\/\/us.milliman.com\/en\/insight\/the-cost-burden-of-blood-cancer-care-in-medicare. Accessed 1 Oct 2024."},{"key":"1797_CR23","unstructured":"University of Michigan Institute for Social Research. Health and retirement study.\u00a0https:\/\/hrs.isr.umich.edu\/about. Accessed 23 Oct 2023"},{"key":"1797_CR24","unstructured":"Produced by the RAND Center for the Study of Aging. RAND HRS Longitudinal File 2020.\u00a0https:\/\/www.rand.org\/well-being\/social-and-behavioral-policy\/portfolios\/aging-longevity\/dataprod\/hrs-data.html."},{"key":"1797_CR25","unstructured":"National Cancer Institute SEER Program. Observational research in Oncology Toolbox.\u00a0https:\/\/seer.cancer.gov\/oncologytoolbox\/. Accessed 9\/27\/2023."},{"key":"1797_CR26","unstructured":"Centers for Medicare & Medicaid Services. \u201cOncology Care Model Memoradum of Understanding.\u201d https:\/\/www.cms.gov\/priorities\/innovation\/files\/x\/ocm-mou.pdf. Accessed 7\/18\/2024."},{"key":"1797_CR27","unstructured":"National Cancer Institute SEER Program. Casefinding lists. https:\/\/seer.cancer.gov\/tools\/casefinding\/. Accessed 9\/1\/2023."},{"key":"1797_CR28","doi-asserted-by":"crossref","unstructured":"Smith GL\u00a0et al.\u00a0\u201cNavigating financial toxicity in patients with cancer: a multidisciplinary management approach\u201d CA: Cancer J Clin 2022;72(5)437\u2013453.","DOI":"10.3322\/caac.21730"},{"key":"1797_CR29","doi-asserted-by":"crossref","unstructured":"Bradley CJ, Yabroff KR, Zafar SY, Shih YCT. \u201cTime to add screening for financial hardship as a quality measure?\u00a0CA: Cancer J Clin 2021;71(2):100\u2013106.","DOI":"10.3322\/caac.21653"},{"key":"1797_CR30","doi-asserted-by":"crossref","unstructured":"Bradley CJ, Eguchi M, Perraillon MC. Factors associated with use of high-cost agents for the treatment of metastatic non\u2013small cell lung cancer.\u00a0JNCI: J Nat Cancer Inst 2020;112(8):802\u2013809.","DOI":"10.1093\/jnci\/djz223"},{"issue":"2","key":"1797_CR31","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1097\/CJI.0000000000000253","volume":"42","author":"V Verma","year":"2019","unstructured":"Verma V, et al. Racial and insurance-related disparities in delivery of immunotherapy-type compounds in the United States. J Immunother. 2019;42(2):55\u201364.","journal-title":"J Immunother"},{"key":"1797_CR32","unstructured":"Fund TCW. State options for making hospital financial assistance programs more accessible. https:\/\/www.commonwealthfund.org\/blog\/2024\/state-options-making-hospital-financial-assistance-programs-more-accessible. Accessed 13 Jan 2025"},{"key":"1797_CR33","doi-asserted-by":"crossref","unstructured":"Bradley CJ, Liang R, Lindrooth RC, Sabik LM, Perraillon MC. High-cost cancer drug use in medicare advantage and traditional Medicare. in JAMA Health Forum. 2025;6(1: American Medical Association):e244868-e244868.","DOI":"10.1001\/jamahealthforum.2024.4868"},{"key":"1797_CR34","doi-asserted-by":"crossref","unstructured":"Wouters OJ, Sullivan SD, Cousin EM, Gabriel N, Papanicolas I, Hernandez I. Drug prices negotiated by Medicare vs US net prices and prices in other countries. JAMA\u00a02024.","DOI":"10.1001\/jama.2024.22582"},{"issue":"4","key":"1797_CR35","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1200\/JCO.19.01564","volume":"38","author":"KR Yabroff","year":"2020","unstructured":"Yabroff KR, Bradley C, Shih Y-CT. Understanding financial hardship among cancer survivors in the United States: strategies for prevention and mitigation. J Clin Oncol. 2020;38(4):292.","journal-title":"J Clin Oncol"}],"container-title":["Journal of Cancer Survivorship"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11764-025-01797-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11764-025-01797-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11764-025-01797-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T10:09:42Z","timestamp":1792231782000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11764-025-01797-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,16]]},"references-count":35,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["1797"],"URL":"https:\/\/doi.org\/10.1007\/s11764-025-01797-2","relation":{},"ISSN":["1932-2259","1932-2267"],"issn-type":[{"value":"1932-2259","type":"print"},{"value":"1932-2267","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,16]]},"assertion":[{"value":"11 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This is an observational study. The study was determined to be exempt by the Colorado Multiple Institutional Review Board.","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}